• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding Ltd (OP: RHHVF )

    299.84 -2.98 (-0.98%)
    Streaming Delayed Price Updated: 3:45 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Roche Holding Ltd

    < Previous 1 2 3 4 5 6 Next >
    Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
    Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. 
    Via Benzinga
    Exposures COVID-19
    Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
    Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen... 
    Via Benzinga
    Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
    Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti 
    Via Benzinga
    Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
    Roche Holding AG (OTC: RHHBY) has agreed to 
    Via Benzinga
    Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
    Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)... 
    Via Benzinga
    Exposures Product Safety
    Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
    Roche Holdings AG's (OTC: RHHBY) nine months  
    Via Benzinga
    Exposures COVID-19
    What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
    Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:  
    Via Benzinga
    Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
    Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
    Via Benzinga
    Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
    Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
    Via Benzinga
    Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
    In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
    Via Benzinga
    Exposures COVID-19
    Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
    Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
    Via Benzinga
    Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
    Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)... 
    Via Benzinga
    Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
    The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme 
    Via Benzinga
    Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
    Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
    Via Benzinga
    Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
    Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t 
    Via Benzinga
    Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
    Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
    Via Benzinga
    Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
    Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
    Via Benzinga
    Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
    The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
    Via Benzinga
    Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
    Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to  
    Via Benzinga
    Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
    Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) 
    Via Benzinga
    Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
    Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with... 
    Via Benzinga
    Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma
    The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)... 
    Via Benzinga
    New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
    Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e 
    Via Benzinga
    Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
    Roche Holdings AG's  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)  
    Via Benzinga
    Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline
    Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)  
    Via Benzinga
    FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma
    Via Benzinga
    EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
    The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those... 
    Via Benzinga
    New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
    Via Benzinga
    FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting
    Via Benzinga
    Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.